The correction of anemia in patients with the combination of chronic kidney disease and congestive heart failure may prevent progression of both conditions

Clinical and Experimental Nephrology

Volumn 13, Issue 2, 2009, Pages 101-106

  Silverberg, Donald S ^a   Wexler, Dov ^a   Iaina, Adrian ^a   Schwartz, Doron ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Anemia; Erythropoietin; Heart failure; Iron; Renal failure

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; BRAIN PEPTIDE; C REACTIVE PROTEIN; DIURETIC AGENT; ERYTHROPOIETIN; INTERLEUKIN 6; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OXYGEN;

ANEMIA; BRAIN LEVEL; CALORIC INTAKE; CELL ACTIVITY; CHRONIC DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; DEPRESSION; DISEASE COURSE; DRUG DOSE REDUCTION; ENDOTHELIUM CELL; EXERCISE; FUNCTIONAL STATUS; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FILLING; HEART RATE; HEART VENTRICLE HYPERTROPHY; HOSPITALIZATION; HUMAN; IRON DEFICIENCY; KIDNEY FUNCTION; LUNG ARTERY PRESSURE; MITRAL VALVE REGURGITATION; OXYGEN CONSUMPTION; PLASMA VOLUME; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; REVIEW; SLEEP APNEA SYNDROME; STEM CELL; VASODILATATION;

ANEMIA; ERYTHROPOIETIN; HEART FAILURE; HUMANS; IRON; RENAL INSUFFICIENCY, CHRONIC;

EID: 67349129363     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-008-0074-1     Document Type: Review

References (65)

1. SA Hunt WT Abraham MC Chin 2005 ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult-summary article J Am Coll Cardiol 46 1116 43
2. DS Silverberg D Wexler A Iaina D Schwartz 2006 The interaction between heart failure and other heart disease and anemia Semin Nephrol 26 296 306
3. JA Lindenfeld 2005 Prevalence of anemia and the effects on mortality in patients with heart failure Am Heart J 149 340 91
4. Tang YD, Katz SD. The prevalence of anemia in chronic heart failure and its impact on the clinical outcomes. Heart Fail Rev. 2008 Feb (ahead of print).
5. IS Anand MA Kuskowski TS Rector 2005 Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-Heft Circulation 112 1121 7 (Pubitemid 41216118)
6. M Komajda SD Anker A Charlesworth 2006 The impact of new onset anemia on morbidity and mortality in chronic heart failure: results from COMET Eur Heart J 27 1441 6 (Pubitemid 43998078)
7. WHW Tang W Tong A Jain GS Francis CM Harris JB Young 2008 Evaluation and long-term prognosis of new-onset, transient and persistent anemia in ambulatory patients with chronic heart failure J Am Coll Cardiol 51 569 76
8. DS Silverberg D Wexler M Blum 2000 The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function, functional cardiac class, and markedly reduces hospitalizations J Am Coll Cardiol 35 1737 44 (Pubitemid 30342851)
9. DS Silverberg D Wexler M Blum 2003 The effect of correction of anemia in diabetics and non diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron Nephrol Dial Transplant 18 141 6 (Pubitemid 36104490)
10. N Vaisman DS Silverberg D Wexler 2004 Correction of anemia in patients with congestive heart failure increases resting energy expenditure Clin Nutr 23 355 61 (Pubitemid 38811673)
11. DS Silverberg D Wexler M Blum 2005 Effects of treatment with EPO beta on outcomes in patients with anaemia and chronic renal failure Kidney Blood Press Res 28 41 7 (Pubitemid 40073624)
12. J George E Goldstein A Abashidze 2005 Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner Cardiovasc Res 68 299 306 (Pubitemid 41428426)
13. M Zilberman DS Silverberg I Bits 2007 Improvement of anemia with erythropoietin and intravenous iron reduces sleep related breathing disorders (SRBD) and improves daytime sleepiness in anemic congestive heart failure (CHF) patients Am Heart J 154 870 6 (Pubitemid 47632499)
14. DS Silverberg D Sheps D Wexler 2001 The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study J Am Coll Cardiol 37 1775 80 (Pubitemid 32499958)
15. Comin-Colet J, Ruiz-Ruiz V, Ortega A et al. Influence of neurohormonal activation and outcome of correction of mild anemia with intravenous iron and erythropoietin in patients with chronic heart failure and cardio-renal-anemia syndrome. Eur Heart J. 2006;28:Abstract 269.
16. Cosyns B, Lancellotti P, Velez-Roa S, Mantia M, Pierard LA. Does treatment with erythropoietin improve left ventricular systolic performance and mitral regurgitation in anemic patients with chronic heart failure and renal insufficiency? Eur Heart J. 2006;27: Abstract 339.
17. KD Pappas CD Gouva KP Katopodis 2007 Correction of anemia with erythropoietin in chronic kidney disease (stage 3 or 4): effects on cardiac performance Cardiovasc Drugs Ther 22 37 44
18. DM Mancini SD Katz C Lang 2003 Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure Circulation 107 294 9 (Pubitemid 36135227)
19. Parissis JT, Kourea K, Panou F et al. Effects of darbepoetin α on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am Heart J. 2008;155:751.e1-7.
20. Kourea K, Parissis JT, Farmakis D et al. Effects of darbepoetin-alfa on plasma pro-inflammatory cytokines, anti-inflammatory cytokine interleukin 10 and soluble Fas/Fas ligand system in anemic patients with chronic heart failure. Atherosclerosis. 2008;199:215-21.
21. K Kourea JT Parissis D Farmakis 2008 Effects of darbepoetin-alfa on quality of life and emotional stress in anemic patients with chronic heart failure Eur J Cardiovasc Prev Rehabil 15 365 9
22. Palazzuoli A, Silverberg DS, Iovine F, et al. Erythropoietin improves anemia, exercise tolerance, and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J. 2006;152: 1096e9-15.
23. Palazzuoli A, Silverberg DS, Iovine F et al. Effects of beta Erythropoietin on left ventricular remodeling, systolic function and beta-type Natriuretic peptide levels in patients with cardio-renal anemia syndrome. Am Heart J. 2007;154:645e9-15.
24. Ghali JK, Anand IS, Abraham WT et al. The effects of increased hemoglobin concentration on clinical outcomes in patients with symptomatic heart failure and anemia: results from STAMINA-Heft. Am Heart Assoc meeting Chicago. Nov 2006: Abstract 2736.
25. J Ghali I Anand WT Abraham 2008 Randomized double blind trial of darbepoetin alpha treatment in patients with symptomatic heart failure and anemia Circulation 117 526 35
26. DJ Van Veldhuisen K Dickstein A Cohen-Solal 2007 Randomized double blind placebo-controlled trial to evaluate the effect of two dosing regimens of darbepoetin alpha in patients with heart failure and anaemia Eur Heart J 28 2208 16 (Pubitemid 47428946)
27. P Ponikowski SD Anker J Szachniewicz 2007 Effect of darbepoetin alpha on exercise tolerance in anemic patients with symptomatic chronic heart failure J Am Coll Cardiol 49 753 62
28. Abraham WT, Klapholz M, Anand I et al. The effect of darbepoetin alfa treatment on clinical outcomes on anemic patients with symptomatic heart failure: a preplanned pooled analysis of two randomized, double-blind, placebo-controlled trials. Eur J Heart Fail. 2006; 5 Suppl: Abstract 548.
29. CL Bennett SM Silver BT Djulbegovic 2008 Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia JAMA 299 914 24
30. JD Rizzo MR Somerfield KL Hagerty 2008 Use of epoetin and darbepoetin in patients with cancer: 2007 American society of hematology/American society of clinical oncology clinical practice guideline update Blood 111 25 41
31. A Besarab WK Bolton JK Browne 1998 The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin N Engl J Med 39 584 90 (Pubitemid 28385655)
32. AK Singh L Szczech KL Tang 2006 Correction of anemia with epoetin alfa in chronic kidney disease N Engl J Med 355 2085 98
33. TB Drueke F Locatelli N Clyne 2006 Normalization of haemoglobin level in patients with chronic kidney disease and anemia N Engl J Med 355 2071 84
34. GFM Strippoli G Tognoni SK Navaneethan A Nicolluci JC Craig 2007 Haemoglobin targets: we were wrong, time to move on Lancet 369 346 50 (Pubitemid 46188478)
35. A Phrommintikul SJ Haas M Elsik H Krum 2007 Mortality and target hemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis Lancet 369 381 8 (Pubitemid 46188479)
36. MO Arcasoy 2008 The non-haematopoietic biological effects of erythropoietin Br J Haematol 141 14 31
37. AP Bolger FP Bartlett HS Penston 2006 Intravenous iron alone for the treatment of anemia in patients with chronic heart failure J Am Coll Cardiol 48 1225 7 (Pubitemid 44345150)
38. J Toblli A Lombrana P Duarte F Di Gennaro 2007 Intravenous iron reduces NT- pro-BNP in anemic patients with chronic heart failure and renal insufficiency J Am Coll Cardiol 50 1657 65 (Pubitemid 47562670)
39. RI Usmanov EB Zueva DS Silverberg M Shaked 2008 Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic renal insufficiency J Nephrol 21 236 42
40. DO Okonko A Grzeslo T Witkowski 2008 Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency J Am Coll Cardiol 51 103 12
41. C Opasich M Cazzola L Scelsi 2005 Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure Eur Heart J 26 2232 7 (Pubitemid 41541385)
42. JN Nanas C Matsouka D Karageorgopoulos 2006 Etiology of anemia in patients with advanced heart failure J Am Coll Cardiol 48 2485 9
43. Anand IS. Heart Failure and anemia: mechanisms and pathophysiology. Heart Fail Rev. 2008 (ahead of print).
44. DW Coyne T Kapoian W Suki 2007 Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the dialysis patients' response to IV Iron with elevated ferritin (DRIVE) study J Am Soc Nephrol 8 975 84 (Pubitemid 46434515)
45. T Kapoian NB O'Mara AK Singh 2008 Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin J Am Soc Nephrol 19 372 9
46. L Gotloib DS Silverberg R Fudin A Shostak 2006 Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron J Nephrol 19 161 7 (Pubitemid 44420105)
47. G Mircescu L Garneata C Capusa N Ursea 2006 Intravenous iron supplementation for the treatment of anemia in predialyzed chronic renal failure patients Nephrol Dial Transplant 21 120 4 (Pubitemid 43057119)
48. Weiss G, Gordeuk VR. Benefits and risks of iron therapy for chronic anemias. Eur J Clin Invest. 2005;35 Suppl 3:36-45.
49. Sengolge G, Horl WH, Sunder-Plassmann GS. Intravenous iron therapy: well tolerated but not harmless. Eur J Clin Invest. 2005;35 Suppl 3:46-51.
50. JO Kang C Jones B Brothwell 1998 Toxicity associated with iron overload found in hemochromatosis: possible mechanism in a rat model Clin Lab Sci 11 350 4
51. Y Maruyama M Nakayama K Yoshimura 2007 Effect of repeated intravenous iron administration in hemodialysis patients on serum 8-hydroxy-2-deoxyguanosine levels Nephrol Dial Transplant 22 1407 12 (Pubitemid 47072230)
52. K Yoshimura H Nakano K Yokoyama M Nakayama 2005 High iron storage levels are associated with increased DNA oxidative injury in patients on regular hemodialysis Clin Exp Nephrol 9 158 63 (Pubitemid 40875107)
53. T Nakamura RF Keep Y Hua S Nagao JT Hoff G Xi 2006 Iron-induced oxidative brain injury after experimental intracerebral hemorrhage Acta Neurochir Suppl 96 194 8
54. HI Feldman M Joffe B Robinson 2004 Administration of parenteral iron and mortality among hemodialysis patients J Am Soc Nephrol 15 1623 32 (Pubitemid 38679688)
55. K Kalantar-Zadeh DL Regidor CJ McAllister B Michael DG Warnock 2005 Time-dependent associations between iron and mortality in hemodialysis patients J Am Soc Nephrol 16 3070 80
56. B Hoen M Paul-Dauphin D Hestin M Krssler 1998 EPIBACTIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients J Am Soc Nephrol 9 869 76 (Pubitemid 28209097)
57. Grune T, Sommerburg O, Siems WG. Oxidative stress in anemia. Clin Nephrol. 2000;53 Suppl 1: S18-22.
58. Ludat K, Sommerburg O, Grune T, Siems WG, Riedel E, Hampl H. Oxidation parameters in complete correction of renal anemia. Clin Nephrol. 2000;53 Suppl 1: S30-5.
59. MA Pfeffer 2007 An ongoing study of anemia correction in chronic kidney disease N Engl J Med 356 959 61 (Pubitemid 46339926)
60. DJ van Veldhuisen JJV McMurray 2007 Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomized outcome trial Eur Heart J 9 110 2 (Pubitemid 46394086)
61. AK Singh S Fishbane 2008 The optimal hemoglobin in dialysis patients-a critical review Semin Dial 21 1 6
62. US Food and Drug Administration: information for healthcare professionals erythropoiesis stimulating agents (ESA). FDA Alert. Nov 8 2007. http://www.fda.gov/cder/drug/InfoSheets/HCP/RHE200711HCP.htm
63. JB Young WY Abraham NM Albert 2008 Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry) Am J Cardiol 101 223 30
64. TE Owan DO Hodge RM Herges SJ Jacobsen VL Roger MM Redfield 2006 Secular trends in renal dysfunction and outcomes in hospitalized heart failure patients J Cardiac Fail 12 257 62
65. L De Luca A Mebazaa G Filippatos 2008 Overview of emerging pharmacologic agents for acute heart failure syndromes Eur J Heart Fail 10 201 13